Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more and get updates at SpurTherapeutics.com.
This site will remain live until Q4 2024 as we transition content to our new site.
If you have an inquiry about SwanBio,
we’d love to hear from you!
Please complete the form or email us at: info@swanbiotx.com.
For any inquiries related to SwanBio’s clinical trials or studies, please email us at clinicaltrials@swanbiotx.com or call us at +1 (267) 417-6356. Click here to learn more about the CYGNET Study and here to learn more about the PROPEL Study.
To learn about SwanBio and compassionate use, click here.
Thank you for your interest.
HEADQUARTERS & MAILING ADDRESS:
150 Monument Rd
Bala Cynwyd
PA 19004
CAMBRIDGE INNOVATION CENTER:
1 Broadway
Cambridge
MA 02142
Social:
